PF icon
Feature Partner

Clairvoyant Therapeutics

Quick Overview of Clairvoyant Therapeutics

Company Status
Public
Private
Non-Profit
Parent Company
CSE Ticker
FSE TICKER
OTC Ticker
TSX TICKER
TSX Venture TICKER
NEO TICKER
NASDAQ TICKER
NYSE TICKER

Company Summary

Clairvoyant Therapeutics is a Canadian biotechnology company developing a quick-to-market clinical strategy designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.





Clairvoyant is focused on the clinical validation of psilocybin in Canada, E.U. & the U.K. with a primary focus on CLARITY, the company's Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder.